FCGRT and myasthenia gravis: Both the approved FcRN-inhibition phase 3 trials included MuSK-MG patients (Fig. 3 and Table 1) (six in ADAPT, and 21 in MycarinG) and in 2023 Rozanolixizumab became the first FDA-licensed MuSK-MG agent in addition to being approved for AChR-antibody disease [46].